These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 38008698)

  • 1. Effect of a monitored exercise protocol in cerebral and hepatic hemodynamics in patients with cirrhosis and portal hypertension.
    Macías-Rodríguez RU; Ruiz-Margáin A; Román-Calleja B; Cantú-Brito C; Flores-Silva F; Gabutti-Thomas A; Aguilar-Nájera O; Cruz-Contreras M; Weber-Sangri L; Ríos-Torres S; Delgadillo AT; Aguilar-Salinas CA; Kershenobich-Stalnikowitz D
    Dig Liver Dis; 2024 May; 56(5):827-835. PubMed ID: 38008698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.
    Abraldes JG; Albillos A; Bañares R; Turnes J; González R; García-Pagán JC; Bosch J
    Gastroenterology; 2009 May; 136(5):1651-8. PubMed ID: 19208350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension.
    Garcia-Tsao G; Bosch J; Kayali Z; Harrison SA; Abdelmalek MF; Lawitz E; Satapathy SK; Ghabril M; Shiffman ML; Younes ZH; Thuluvath PJ; Berzigotti A; Albillos A; Robinson JM; Hagerty DT; Chan JL; Sanyal AJ;
    J Hepatol; 2020 May; 72(5):885-895. PubMed ID: 31870950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physical exercise increases portal pressure in patients with cirrhosis and portal hypertension.
    García-Pagàn JC; Santos C; Barberá JA; Luca A; Roca J; Rodriguez-Roisin R; Bosch J; Rodés J
    Gastroenterology; 1996 Nov; 111(5):1300-6. PubMed ID: 8898644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized study of losartan vs propranolol: Effects on hepatic and systemic hemodynamics in cirrhotic patients.
    Castaño G; Viudez P; Riccitelli M; Sookoian S
    Ann Hepatol; 2003; 2(1):36-40. PubMed ID: 15094704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension.
    La Mura V; Reverter JC; Flores-Arroyo A; Raffa S; Reverter E; Seijo S; Abraldes JG; Bosch J; García-Pagán JC
    Gut; 2011 Aug; 60(8):1133-8. PubMed ID: 21427197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-selective β-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis.
    Reiberger T; Ferlitsch A; Payer BA; Pinter M; Homoncik M; Peck-Radosavljevic M;
    J Gastroenterol; 2012 May; 47(5):561-8. PubMed ID: 22170417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Sapropterin on Portal and Systemic Hemodynamics in Patients With Cirrhosis and Portal Hypertension: A Bicentric Double-Blind Placebo-Controlled Study.
    Reverter E; Mesonero F; Seijo S; Martínez J; Abraldes JG; Peñas B; Berzigotti A; Deulofeu R; Bosch J; Albillos A; García-Pagán JC
    Am J Gastroenterol; 2015 Jul; 110(7):985-92. PubMed ID: 26077176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 2 randomised controlled trial of serelaxin to lower portal pressure in cirrhosis (STOPP).
    Gifford FJ; Dunne PDJ; Weir G; Ireland H; Graham C; Tuck S; Hayes PC; Fallowfield JA
    Trials; 2020 Mar; 21(1):260. PubMed ID: 32164767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of sarcopenia on prognostic value of cirrhosis: going beyond the hepatic venous pressure gradient and MELD score.
    Kang SH; Jeong WK; Baik SK; Cha SH; Kim MY
    J Cachexia Sarcopenia Muscle; 2018 Oct; 9(5):860-870. PubMed ID: 30371017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hepatic transit times and liver elasticity compared with meld in predicting a 1 year adverse clinical outcome of a clinically diagnosed cirrhosis].
    Koller T; Piešťanská Z; Hlavatý T; Holomáň J; Glasa J; Payer J
    Vnitr Lek; 2016; 62(5):351-9. PubMed ID: 27319227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of verapamil on hepatic and systemic hemodynamics and liver function in patients with cirrhosis and portal hypertension.
    Navasa M; Bosch J; Reichen J; Bru C; Mastai R; Zysset T; Silva G; Chesta J; Rodés J
    Hepatology; 1988; 8(4):850-4. PubMed ID: 3391511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis.
    Lens S; Alvarado-Tapias E; Mariño Z; Londoño MC; LLop E; Martinez J; Fortea JI; Ibañez L; Ariza X; Baiges A; Gallego A; Bañares R; Puente A; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; Forns X; García-Pagán JC
    Gastroenterology; 2017 Nov; 153(5):1273-1283.e1. PubMed ID: 28734831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Measurement of hepatic venous pressure gradient in liver cirrhosis: relationship with the status of cirrhosis, varices, and ascites in Korea].
    Kim MY; Baik SK; Suk KT; Yea CJ; Lee IY; Kim JW; Cha SH; Kim YJ; Um SH; Han KH
    Korean J Hepatol; 2008 Jun; 14(2):150-8. PubMed ID: 18617762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension.
    Afdhal N; Everson GT; Calleja JL; McCaughan GW; Bosch J; Brainard DM; McHutchison JG; De-Oertel S; An D; Charlton M; Reddy KR; Asselah T; Gane E; Curry MP; Forns X
    J Viral Hepat; 2017 Oct; 24(10):823-831. PubMed ID: 28295923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-invasive aspartate aminotransferase to platelet ratio index correlates well with invasive hepatic venous pressure gradient in cirrhosis.
    Kirnake V; Arora A; Sharma P; Goyal M; Chawlani R; Toshniwal J; Kumar A
    Indian J Gastroenterol; 2018 Jul; 37(4):335-341. PubMed ID: 30178093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension.
    Lens S; Baiges A; Alvarado-Tapias E; LLop E; Martinez J; Fortea JI; Ibáñez-Samaniego L; Mariño Z; Rodríguez-Tajes S; Gallego A; Bañares R; Puente Á; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; García-Pagán JC; Forns X
    J Hepatol; 2020 Dec; 73(6):1415-1424. PubMed ID: 32535060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of worsening portal hypertension during long-term medical treatment in patients with cirrhosis who had been classified as early good-responders on haemodynamic criteria.
    Merkel C; Bolognesi M; Berzigotti A; Amodio P; Cavasin L; Casarotto IM; Zoli M; Gatta A
    J Hepatol; 2010 Jan; 52(1):45-53. PubMed ID: 19914730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study.
    Berzigotti A; Albillos A; Villanueva C; Genescá J; Ardevol A; Augustín S; Calleja JL; Bañares R; García-Pagán JC; Mesonero F; Bosch J;
    Hepatology; 2017 Apr; 65(4):1293-1305. PubMed ID: 27997989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Underlying mechanism of portal hypertensive gastropathy in cirrhosis: a hemodynamic and morphological approach.
    Curvêlo LA; Brabosa W; Rhor R; Lanzoni V; Parise ER; Ferrari AP; Kondo M
    J Gastroenterol Hepatol; 2009 Sep; 24(9):1541-6. PubMed ID: 19743998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.